RJ Hamster
Altucher: My #1 FREE Stock Pick is NYSE: (_)
APRIL 21, 2026 | READ ONLINE
Below is an important message from one of our highly valued sponsors. Please read it carefully as they have some special information to share with you.
Dear Reader,
In this short 3-min. video, legendary investor James Altucher reveals the name and ticker symbol of a company he believes will skyrocket as soon as March 26th…
100% FREE of charge.
No tricks.
No gimmicks.
Free.
The company he reveals here is directly tied to the hotly anticipated IPO of Elon Musk’s Starlink…
Which is estimated to be worth $100 BILLION when it finally goes public.
That would make it the biggest IPO in history!
And right now – today…
You can get a “pre-IPO” recommendation on Starlink before it goes public…
From one of the most successful investors in the world – completely FREE of charge.
Click here to watch the video now.
It’s only 3 minutes long…
And it could give you an early stake in one of the biggest profit opportunities of all time.
Click here to check it out before it’s too late.
Best,
Matt Insley
Publisher, Paradigm Press
P.S. Starlink could go public as soon as March 26th. So for your chance at the biggest possible gains…
Make sure you act on this ASAP.
Click here to watch James’ urgent 3 min. video now.
This Month’s Featured Content
Top 5 Insider Buys From Q1: Buy, Sell, or Hold in Q2?
Reported by Thomas Hughes. First Published: 4/6/2026.
KEY POINTS
- Insiders were active in Q1, but insider buying isn’t enough to warrant an investor buy; diligence is due.
- Institutional and analyst trends are better indicators of a stock’s price direction.
- Each stock on this list has a catalyst to drive it higher, and risks to offset the opportunity.
- Special Report: You’re Being LIED To About The Iran War (From Banyan Hill Publishing)
Insiders bought stock in Q1 2026, signaling conviction in their businesses and full-year outlooks. The question for investors is whether Q2 is a good time to buy, sell, or hold these names—the answer depends on broader market drivers and how each stock fits into a portfolio.
E.W. Scripps: Most Bought by Insiders in Q1 2026
E.W. Scripps (NASDAQ: SSP) logged the most insider buying in Q1. InsiderTrades tracked 34 purchases by 16 insiders, including multiple transactions by family owners. Their concerted activity reflects confidence in a multiyear turnaround intended to deliver EBITDA growth by 2028. Initiatives include a stronger focus on streaming, divesting underperforming assets and acquiring higher-performing media properties to improve scale and cost ratios.
ALTUCHER: THIS IS MY FAVORITE FREE STARLINK PRE-IPO TICKER (AD)
In the next 3 minutes…
James Altucher – legendary investor and venture capitalist…
And someone who’s known for playing his cards “close to the vest”…
Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…
Click here to watch this short 3-minute video now.
Institutions are also buying. They own nearly 70% of the stock and added shares in Q1, providing a solid support base. Analysts, however, are not fully onboard yet: although coverage has increased, rating revisions are mixed and sentiment leans toward Reduce. Price targets remain relatively high, and even the low end implies upside. Potential catalysts this year include mid-cycle election spending, margin improvement, stronger cash flow and debt reduction.
W.R. Berkley Is Getting Accumulated in 2026
W.R. Berkley (NYSE: WRB) saw 37 recorded acquisitions in Q1, but almost all were tied to a single major buyer: Sumitomo Insurance Company of Japan. Sumitomo, a leading global property insurer, is expanding its U.S. presence and is targeting roughly a 15% stake. Including Q1 activity, insiders now own about 25% of the company.
Institutions—including Sumitomo—own nearly 70% of WRB and were net buyers in Q1, purchasing at roughly a 4-to-1 pace, which helps limit downside. Analysts are more reserved, rating the stock a Hold, but coverage is ample, sentiment is steady and there remains upside potential.
Service Properties Trust Insiders Buy in Bulk
Service Properties Trust (NASDAQ: SVC)ranked highly by share volume. Three insiders bought nearly 42 million shares—mostly director Adam D. Portnoy—raising insider ownership to about 1.5%. While small relative to total float, the purchases signal confidence in the value on offer in 2026. Service Properties Trust is a triple-net REIT focused on gas stations and hotels, operating a portfolio of well-known brands.
Institutions, which own about 84% of the stock, have also been buying. Analysts who rate SVC a Hold see nearly 50% upside potential. Near-term catalysts include restructuring, asset sales and debt reduction; improving travel trends could further boost performance as the year progresses.
Insider Buying Suggests Bottom in Coupang Stock
Coupang (NYSE: CPNG) had a single insider make three purchases, activity that helped establish a market bottom. Early-April technicals remain weak, however, and the stock could face further pressure—potentially reaching the low teens by midyear. A major overhang is a data breach affecting millions of consumers—roughly half of South Korea’s population—and the uncertain business impact of that event.
Institutions own about 85% of Coupang and have been net buyers for more than six consecutive quarters, increasing activity into Q1 2026. Analyst trends are mixed-to-positive: 11 rate it a Hold, with consensus price targets implying roughly 40% upside. Catalysts include international expansion, AI-driven efficiencies and recovery efforts following the breach.
Korro Bio: Broad-Based Insider Buying and Sell-Side Support
Korro Bio (NASDAQ: KRRO) stands out for broad-based insider buying. More than a dozen insiders and major shareholders purchased shares in Q1, bringing insider ownership to about 4.6%. Institutions hold roughly 13% as of early April and are accumulating on balance. Analysts are relatively bullish: 11 rate KRRO a consensus Moderate Buy, implying roughly 150% upside.
Key catalysts include progress on gene-editing therapies after a major restructuring. The company reports sufficient liquidity through 2028 but will need to commercialize its technology by then. Near-term triggers to watch are regulatory filings and clinical testing programs for candidate therapies.
Update your email preferences or unsubscribe here
© 2026 The Markets Daily
345 N Reid Place #620
Sioux Falls, SD 57106, United StatesTerms of Service
